
Invivyd Inc (IVVD) Stock Forecast & Price Target
Invivyd Inc (IVVD) Analyst Ratings
Bulls say
Invivyd is a biopharmaceutical company that is developing monoclonal antibody therapies to prevent and treat serious viral infectious diseases. The company's lead product, PEMGARDA, has received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in immunocompromised individuals and is expected to see continued growth in sales. Invivyd also has promising next-generation antibody candidates, VYD2311 for COVID-19 and VBY329 for RSV infections, and a strong pipeline targeting other viral diseases like measles. With a positive outlook on the company's future success and proven track record of producing effective anti-SARS-CoV-2 antibodies, Invivyd's continued growth is expected and is a strong investment opportunity.
Bears say
Invivyd is focused on developing monoclonal antibodies for COVID-19 and other serious viral diseases, but with a lead mAb already approved and a longer-term mAb in development, their pipeline may be limited. Additionally, the company's reliance on one product for a significant portion of their revenue presents financial risk, especially in the unpredictable and competitive pharmaceutical industry. Finally, the company's relatively small size and lack of diversification make it susceptible to changes in market conditions and regulatory challenges.
This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.
Invivyd Inc (IVVD) Analyst Forecast & Price Prediction
Start investing in Invivyd Inc (IVVD)
Order type
Buy in
Order amount
Est. shares
0 shares